Active Ingredient History
Monalizumab, a humanized anti-NKG2A antibody(formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies and other cancers. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Arthritis, Rheumatoid (Phase 1)
Breast Neoplasms (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Squamous Cell (Phase 1/Phase 2)
Colorectal Neoplasms (Phase 2)
COVID-19 (Phase 2)
Esophageal Neoplasms (Phase 1/Phase 2)
Genital Neoplasms, Female (Phase 1)
Head and Neck Neoplasms (Phase 2)
Hematologic Neoplasms (Phase 1)
Inflammation (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1/Phase 2)
Microsatellite Instability (Phase 2)
Neoplasms (Phase 2)
Sepsis (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue